What is claimed is:

1. Use of an OX40 agonist and an anti-CTLA4 antibody in the manufacture of a medicament for the treatment of a tumor in a subject, wherein

(a) the medicament is to be administered to the subject a first time,

(b) a measurement of cells that indicates a reduction in macrophage differentiation in the subject is to be obtained following the first administration of the medicament,

(c) chemotherapy is to be administered to the subject a first time following a measurement of cells that indicates a reduction in macrophage differentiation in the subject

(d) the medicament is to be administered to the subject a second time, and

(e) chemotherapy or radiotherapy is to be administered to the subject a second time, wherein the OX40 agonist is an anti-OX40 antibody.

2. The use of claim 1, wherein steps (b) and (d) additionally comprise an anti-IL-4 antibody to be co-administered.

3. The use of either claim 1 or 2, wherein the subject is identified as having a chemoresistant or radiotherapy resistant tumor.

4. The use of any one of claims 1-3, wherein the use delays or reduces tumor growth, reduces tumor size, and/or enhances survival in the subject.

5. The use of any one of claims 1-4, wherein the tumor is chemoresistant or radiotherapy resistant.

6. The use of any one of claims 1-5, wherein the tumor is non-immunogenic or poorly immunogenic.

7. The use of claim 6, wherein the tumor has poor infiltration of CD8 T cells.

8. The use of any one of claims 1-7, wherein the subject has pancreatic cancer or pancreatic adenocarcinoma.

9. The use of any one of claims 1-8, wherein the tumor is a pancreatic cancer or pancreatic adenocarcinoma.

10. The use of any one of claims 1-9, wherein the chemotherapy comprises gemcitabine to be administered.

11. The use of any one of claims 1-10, wherein the anti-OX40 antibody is one or more of OX86, humanized anti-OX40 antibody, and 9B12.

12. The use of any one of claims 1-11, wherein the anti-CTLA4 antibody is one or more of 9D9 and tremelimumab.

13. The use of either claim 1 or 2, wherein said therapy is to be administered when immune cell differentiation is reduced in the tumor environment, wherein the immune cell is one or more of a macrophage or T cell.

14. The use of claim 13, wherein a reduction in macrophage differentiation is determined by a decrease in arginase expression in a macrophage.

15. The use of any of claims 1-2, wherein the chemotherapy or radiotherapy is to be administered 1, 2, 3, 4, 5, or 6 days after administration of the medicament.

16. The use of any one of claims 1-15, wherein the medicament, and said therapy are to be administered to the subject two or more times.

17. The use of any one of claims 1-8, wherein the subject has colorectal cancer.